Skip to main content
Multiple Sclerosis Discovery Forum
User Top Menu
Who We Are
How to Cite
News & Future Directions
Essays & Opinions
Meetings & Events
Clinical Trials - Public Availability of Results
MS trials baseline
Map of MS Prevalence
Progressive MS Authors Galaxy
Ongoing Clinical Trials in MS
MRI-Related Clinical Trials
RRMS and CIS
Immunopathogenesis of MS
The MS Galaxy
ARR in Placebo Groups
Scientific Literature TreeMap
Clinical Trials in MS
Click Here to Support MSDF
You are here
Most Viewed Papers
In vivo clonotypic regulation of human myelin basic protein-reactive T cells by T cell vaccination.
Interferon-beta-1b-induced short- and long-term signatures of treatment activity in multiple sclerosis.
Commentary: Outcome measures were flawed.
Significant Reduced Loss of Brain Volume in Multiple Sclerosis Patients Treated with COPAXONE(R)
Estimating a treatment effect: Choosing between relative and absolute measures.
The transcriptome of mouse central nervous system myelin.
Survival in MS: a randomized cohort study 21 years after the start of the pivotal IFNβ-1b trial.
The Histology of Disseminated Sclerosis
Sustained low rate of brain volume loss under long-term fingolimod treatment in relapsing multiple sclerosis: results from the LONGTERMS study
Reduction in IL-10 producing B cells (Breg) in multiple sclerosis is accompanied by a reduced naïve/memory Breg ratio during a relapse but not in remission.
Eight cases of insular sclerosis of the brain and spinal cord.
Pathological Anatomy: Illustrations of the elementary forms of disease.
Multiple Sklerose und Erbanlage
MRI monitoring of immunomodulation in relapse-onset multiple sclerosis trials.
Multiple sclerosis from the standpoint of geographic distribution and race
Disseminated sclerosis in South Africa; its relationship to swayback disease and suggested treatment.
Optical coherence tomography in multiple sclerosis: a systematic review and meta-analysis.
Some comments on the relationship of the distribution of multiple sclerosis to latitude, solar radiation, and other variables.
Critical Review: disseminated sclerosis
Gray matter atrophy is related to long-term disability in multiple sclerosis.
Switching from natalizumab to fingolimod: an observational study.
MRI as an outcome in multiple sclerosis clinical trials.
Lectures on the diseases of the nervous system.